Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. 1996

N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

The oxidation of proguanil was studied in 89 unrelated healthy Turkish volunteers after administration of proguanil (single dose, 200 mg, orally). Based on the distribution of the ratio of proguanil to cycloguanil excreted in urine, and using an antimode value of 15, the prevalence of poor metabolizers in a Turkish population was estimated to be 5.6% (95% confidence interval 2.0%-17.3%) which was similar to that in the other Caucasian populations. The relationship between the oxidative capacities of CYP2C19 for the two substrates, proguanil and mephenytoin, was studied in 39 subjects (two poor and 37 extensive metabolizers of proguanil). The two poor metabolizers of proguanil were also identified as poor metabolizers of S-mephenytoin and no misclassification by the two phenotyping methods was observed. The correlation between the metabolic ratio of proguanil to cycloguanil and the S/R-mephenytoin ratio as assessed by Spearman's rank test, was statistically significant (rs = 0.50, P < 0.001).

UI MeSH Term Description Entries
D008297 Male Males
D008617 Mephenytoin An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias. Methoin,Methyl Phenetoin,5-Ethyl-3-Methyl-5-Phenylhydantoin,Mefenetoin,Mesantoin,Phenantoin,5 Ethyl 3 Methyl 5 Phenylhydantoin,Phenetoin, Methyl
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011153 Population The total number of individuals inhabiting a particular region or area. School Age Population,School-Age Population,Population, School Age,Population, School-Age,Populations,Populations, School Age,Populations, School-Age,School Age Populations,School-Age Populations
D002727 Proguanil A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent. Chlorguanid,Chloroguanide,Bigumal,Chloriguane,Chloroguanide Hydrochloride,Paludrin,Paludrine,Proguanil Hydrochloride,Hydrochloride, Chloroguanide,Hydrochloride, Proguanil
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
April 1995, British journal of clinical pharmacology,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
August 1999, British journal of clinical pharmacology,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
August 1993, British journal of clinical pharmacology,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
March 1996, Clinical pharmacology and therapeutics,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
June 1995, Clinical pharmacology and therapeutics,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
June 1996, Pharmacogenetics,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
November 1995, Clinical pharmacology and therapeutics,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
March 1995, British journal of clinical pharmacology,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
November 1994, British journal of clinical pharmacology,
N E Basci, and A Bozkurt, and S Kortunay, and A Isimer, and A Sayal, and S O Kayaalp
March 1993, British journal of clinical pharmacology,
Copied contents to your clipboard!